New study tests which chemo combo works best for common breast cancers

NCT ID NCT04193059

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 3 trial compares two chemotherapy regimens for women with non-triple negative breast cancer after surgery. One group gets epirubicin plus cyclophosphamide followed by docetaxel (EC-T), the other gets paclitaxel plus carboplatin (PCb). The study includes 1560 participants and tracks how long they stay cancer-free. It also looks at side effects and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
chemotherapy drugs (epirubicin, cyclophosphamide, docetaxel, paclitaxel, carboplatin, and trastuzumab)
What this could lead to
If successful, this could show that a carboplatin-based regimen works as well as or better than standard anthracycline-based chemo for certain breast cancer types, potentially reducing side effects.
What could go wrong
This is a single-center trial, so results may not apply broadly. Chemotherapy has well-known side effects like fatigue, nausea, and increased infection risk. The study is not testing a new drug, just comparing existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.